Anaplastic lymphoma kinase (ALK) is validated as a therapeutic molecular target in multiple malignancies. such as non-small cell lung cancer (NSCLC). However. the feasibility of targeted therapies exerted by ALK inhibitors is inevitably hindered owing to drug resistance. https://www.hongmacro.com/product-category/wig-caps/